{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:42:53Z","timestamp":1778607773377,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"15","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.clinbiochem.2016.05.008","type":"journal-article","created":{"date-parts":[[2016,5,18]],"date-time":"2016-05-18T14:09:53Z","timestamp":1463580593000},"page":"1205-1208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas"],"prefix":"10.1016","volume":"49","author":[{"given":"Franck","family":"Patin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Crini\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Francia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peggy","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9ment","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Vayne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Vourc'h","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Benz-de Bretagne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian R.","family":"Andres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Blasco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0005","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","article-title":"Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients","volume":"86","author":"Erickson","year":"2001","journal-title":"J. Clin. Endocrinol. Metab. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0010","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/ncpendmet0396","article-title":"Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005","author":"Pacak","year":"2007","journal-title":"Nat. Clin. Pract. Endocrinol. Metab."},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0015","first-page":"5153","article-title":"Dopamine excess in patients with head and neck paragangliomas","volume":"30","author":"Horst-Schrivers","year":"2010","journal-title":"Anticancer Res. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0020","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0025","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1373\/clinchem.2014.224832","article-title":"Laboratory evaluation of pheochromocytoma and paraganglioma","volume":"60","author":"Eisenhofer","year":"2014","journal-title":"Clin. Chem. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0030","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1210\/jc.2014-1498","article-title":"Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline","volume":"99","author":"Lenders","year":"2014","journal-title":"J. Clin. Endocrinol. Metab. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1210\/jc.2009-1632","article-title":"Increased urinary excretion of 3-methoxytyramine in patients with head and neck paragangliomas","volume":"95","author":"van Duinen","year":"2010","journal-title":"J. Clin. Endocrinol. Metab. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11906-012-0253-z","article-title":"Dopamine, the kidney, and hypertension","volume":"14","author":"Harris","year":"2012","journal-title":"Curr. Hypertens. Rep. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0045","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1530\/eje.0.1470085","article-title":"The value of plasma markers for the clinical behaviour of phaeochromocytomas","volume":"147","author":"Harst","year":"2002","journal-title":"Eur. J. Endocrinol. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0050","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1474-8673.1982.tb00489.x","article-title":"Cardiovascular dopamine receptors: physiological, pharmacological and therapeutic implications","volume":"2","author":"Lokhandwala","year":"1982","journal-title":"J. Auton Pharmacol. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0055","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1373\/clinchem.2010.153320","article-title":"Measurements of plasma methoxytyramine, normetanephrine and metanephrine as discriminators of different hereditary forms of pheochromocytoma","volume":"57","author":"Eisenhofer","year":"2011","journal-title":"Clin. Chem. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0060","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0090-4295(98)00612-8","article-title":"Pheochromocytomas: can malignant potential be predicted?","volume":"53","author":"John","year":"1999","journal-title":"Urology [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0065","doi-asserted-by":"crossref","DOI":"10.1530\/EJE-13-0529","article-title":"Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites","author":"van Duinen","year":"2013","journal-title":"Eur. J. Endocrinol. [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0070","first-page":"555","article-title":"[Significance of 3-methoxytyramine urine measurement in the diagnosis of pheochromocytomas and paragangliomas: about 28 patients]","volume":"69","author":"Le Jacques","year":"2011","journal-title":"Ann. Biol. Clin. (Paris) [Internet]"},{"key":"10.1016\/j.clinbiochem.2016.05.008_bb0075","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1210\/jc.2009-0303","article-title":"Dietary influences on plasma and urinary metanephrines: implications for diagnosis of catecholamine-producing tumors","volume":"94","author":"de Jong","year":"2009","journal-title":"J Clin Endocrinol Metab [Internet]"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201630056X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201630056X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:48:43Z","timestamp":1757864923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201630056X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":15,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S000991201630056X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.05.008","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low specificity of urinary 3-methoxytyramine in screening of dopamine-secreting pheochromocytomas and paragangliomas","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2016.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}